Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis

Uveitis Clinical Trial

Official title:

Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01837056
• Other study ID #: Nuneuveitis
• Status: Completed
• Phase: N/A
• First received: April 12, 2013
• Last updated: April 17, 2013
• Start date: January 2011
• Est. completion date: February 2012

Study information

• Verified date: April 2013
• Source: National Institute of Health, Korea
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis

• serum antibody to T. gondii and T. canis

• PCR with peripheral blood for T. gondii and T. canis

• PCR with aqueous humor for T. gondii and T. canis

• Clinical manifestation of patient with uveitis

Description:

Consecutive patients with uveitis are enrolled in Nune Eye Hospital.

Serum ELISA

• IgM,IgG antibody to Toxoplasma gondii

• IgG antibody to Toxocara canis

PCR

• PCR with serum and aqueous humor to Toxoplasma gondii

• PCR with serum and aqueous humor to Toxocara canis Clinical characteristics

• visual acuity

• intraocular pressure (IOP)

• location and degree of inflammation

• other fundus findings were recorded

questionnaire

• environment, occupation

• pet ownership, exposure to animal

• history of eating raw liver of animal, raw beef or any other raw flesh of animal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 98
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patients with uveitis

Exclusion Criteria:

• Patients with history of major ophthalmic surgery within 6 months

• antiviral, antifungal or antiparasitic therapy within 6 months

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Uveitis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Health, Korea

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	location of inflammation and fundus finding	location of inflammation; anterior or posterior or panuveitis; fundus finding; granuloma in macular or periphery retina; pigmentation	at baseline	No
Other	Demographic characteristics	Gender; Residence; Pet ownership; Habit of eating uncooked meat	at baseline	No
Primary	Number of patients with positive result for serum antibody to Toxoplasma gondii and Toxocara canis	proportion of patients with seropositive for Toxoplasma gondii and Toxocara canis among patients	at baseline	No
Secondary	Number of patients with positive PCR with peripheral blood and aqueous humor to Toxoplasma gondii and Toxocara canis	Proportion of patient with positive PCR to Toxoplasma gondii and Toxocara canis	at baseline	No